CME

Five things for pharma marketers to know: Tuesday, July 21

Five things for pharma marketers to know: Tuesday, July 21

By

Physicians criticize pricing of Orkambi, Vertex's new cystic-fibrosis drug; the EU approves Amgen's PCSK9 inhibitor Repatha; PhRMA boosts lobbying spending in the second quarter

CMS updates CME guidance

CMS updates CME guidance

By

New rules will require manufacturers to report some indirect payments made to physicians for CME activities.

21st Century Cures, Amarin Court Case Advance

21st Century Cures, Amarin Court Case Advance

Pharma's efforts to evolve restrictions about off-label marketing move forward.

House expected to vote on 21st Century Cures

House expected to vote on 21st Century Cures

By

The legislation would allow drugmakers to share information about their products beyond what is included on the FDA-approved label.

Five things for pharma marketers to know: Wednesday, July 1

Five things for pharma marketers to know: Wednesday, July 1

By

Purdue withdraws plans to participate in FDA meeting on painkillers; Allscripts takes 10% stake in NantHealth in advance of IPO; union advocates to end pharma support for CME

21st Century Cures bill advances to House floor

21st Century Cures bill advances to House floor

By

The legislation would allow drugmakers to share economic information with payers beyond what is included on the FDA-approved label.

Lawmakers advance 21st Century Cures draft; proposal would allow sharing of off-label economic data

Lawmakers advance 21st Century Cures draft; proposal would allow sharing of off-label economic data

By

The draft would allow drugmakers to share off-label economic data with payers, a practice that until now has been considered taboo, and require the FDA to assess patient experience data in regulatory decisions, in addition to boosting funding for the NIH.

ACCME tables logo ban again

ACCME tables logo ban again

By

After a wave of feedback, the accreditor has deferred a ban on use of corporate logos in disclosures of commercial support.

ACCME closer to revising criteria

The accreditor wants comments on its new accreditation plan, but a new commendation proposal is yet to come.

Proposed guidelines kick industry off campus

Proposed guidelines kick industry off campus

By

Pew Charitable Trust's proposed conflict of interest guidelines could mean even less face time for sales reps and less industry money for CME programs.

Lippincott deepens CE, research connection

Lippincott deepens CE, research connection

By

The publisher says the latest release enriches the CE experience through direct links to Nursing Advisor content.

OPDP expands "Bad Ad" with CME

OPDP expands "Bad Ad" with CME

By

The agency made good on a pledge to expand Bad Ad with a web-based CME course and case studies representing common problems.

Rebound seen in HCP meeting turnout: report

Rebound seen in HCP meeting turnout: report

By

Attendance by physicians crept up in 2012, said the trade group HCEA, but overall turnout was flat, likely because exhibitors brought less personnel along to meetings.

CME compliance trends up among some outfits

By

Some providers of CME are getting better at complying with accreditation criteria, data show, yet many are still struggling to meet a stricter set of requirements.

CME income rises, despite steep pharma cuts

By

Pharma's med-ed cut was its fifth in a row. But other income surged, filling the void as the funding picture for CME continued to even out.

Industry pushing for further clarity on Sunshine Act

Industry pushing for further clarity on Sunshine Act

By

With a clear buffet exemption in-hand, the agency's position with respect to CME meals seems pretty clear. Industry is pushing for more clarity around the treatment of accrediting bodies.

Study says CME leads to million-dollar savings

By

The estimated cost savings for only 10% of participants changing their practice is somewhere in the million-dollar range, according to a study.

Medscape looks to fill docs' diabetes-testing gap

By

A CME activity was associated with increased testing that could head off neuropathy in patients with type 2 diabetes.

BI, Lilly go simple in new SGLT med-ed effort

BI, Lilly go simple in new SGLT med-ed effort

By

Boehringer Ingelheim and Eli Lilly rolled out a pre-launch SGLT campaign that breaks ranks with branding for J&J's SGLT2 inhibitor Invokana.

Navidea deploying MSLs in launch of new diagnostic agent

Navidea deploying MSLs in launch of new diagnostic agent

By

Medical science liaisons will educate nuclear-medicine clinicians as part of the launch of a new Navidea diagnostic agent for use in breast and skin cancer.

Sunshine spawns fresh questions for med ed

By

New transparency rules set to lay bare financial ties between physicians and pharma will be a mixed bag for medical education, providers say.

CMS releases "Sunshine" final rule: federal preemption, August start date

CMS releases "Sunshine" final rule: federal preemption, August start date

By

CMS issued its long-delayed final rule for collecting data on industry payments to physicians, ordering data collection to begin in August and asserting that the federal law preempts state laws.

M3 Group extends reach in Iberian and Latin American markets with partnership

M3 Group extends reach in Iberian and Latin American markets with partnership

By

MDLinx owner M3 Group is partnering with Argentine online CME firm Medcenter on a content-sharing deal that will expand its in-language reach to Spain, Portugal and Latin America.

Pri-Med in deal to buy EHR firm

By

The med-ed company is buying Amazing Charts, a tie-up the firms say will enable them to deliver customized education to physicians and then assess the patient-level impact.

JAMA taps NEJM's Easley as publisher

JAMA taps NEJM's Easley as publisher

By

The American Medical Association has wooed New England Journal of Medicine publisher Tom Easley to Chicago, where he will preside over the society's publications, soon to be rolled up into the JAMA brand.

Most docs don't know about FDA's opioid safety plan: survey

By

Only 35% of physicians are aware of the FDA's class-wide safety plan for certain opioids, a survey showed, suggesting an awareness challenge as the plan gets under way.

Sunshine Act could scare docs away from commercially-supported CME

Sunshine Act could scare docs away from commercially-supported CME

By

Physicians are reconsidering their participation in industry-sponsored CME, fearful that their inclusion in Sunshine Act databases as having received payments from companies will tarnish their reputations and fuel perceptions of conflicts of interest, a survey has found.

Pharma slashed CME funding again last year: report

By

The drug industry dialed back its continuing medical education (CME) grant-giving in 2011, continuing a negative trend of the last few years.

People news: ACEHP and Preventice

The Alliance for Continuing Education in the Health Professions (ACEHP) named a new executive director, and mobile health app firm Preventice hired a director of global business development.

FDA opioid plan directs funding for CME

By

The FDA's opioid REMS safety plan is challenged on two fronts: getting CME providers to offer courses and getting doctors to attend them. Can the agency's scheme educate enough physicians to curb an epidemic?

Email Newsletters


As US pharma continued its quest for a Grand Prix at the Lions Health international festival of creativity, MM&M went on location to Cannes, France. Missed our coverage from June? Now, we're giving you an opportunity to catch up on some of what you missed. Download our e-book on the two-day festival, recapping the event, rounding up the best of the speakers, offering perspective and listing all of the winners. Click here to download.


The most recent MM&M Skill Sets Live event surveyed a range of issues relating to one of the hottest promotional spaces in healthcare. Speakers and panelists at the morning-long session, including promotional- and multichannel-minded executives from GSK, Epocrates, Treato and Montefiore Medical Center, weighed in on topics designed to help marketers demystify the challenges associated with non-personal promotion. Click here.